

Global Remicade (Infliximab) and Biosimilar Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/GBDAB9787525EN.html>

Date: June 2023

Pages: 77

Price: US\$ 4,480.00 (Single User License)

ID: GBDAB9787525EN

Abstracts

The global Remicade (Infliximab) and Biosimilar market size is expected to reach \$ 3781.3 million by 2029, rising at a market growth of 5.4% CAGR during the forecast period (2023-2029).

Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.

This report studies the global Remicade (Infliximab) and Biosimilar production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Remicade (Infliximab) and Biosimilar, and provides market size (US\$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Remicade (Infliximab) and Biosimilar that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Remicade (Infliximab) and Biosimilar total production and demand, 2018-2029, (K Units)

Global Remicade (Infliximab) and Biosimilar total production value, 2018-2029, (USD Million)

Global Remicade (Infliximab) and Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Remicade (Infliximab) and Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Remicade (Infliximab) and Biosimilar domestic production, consumption, key domestic manufacturers and share

Global Remicade (Infliximab) and Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Remicade (Infliximab) and Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Remicade (Infliximab) and Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)

This reports profiles key players in the global Remicade (Infliximab) and Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include J & J, Pfizer, Organon and Amgen, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Remicade (Infliximab) and Biosimilar market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), volume (production, consumption) & (K Units) and average price (US\$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Remicade (Infliximab) and Biosimilar Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Remicade (Infliximab) and Biosimilar Market, Segmentation by Type

Brand

Biosimilar

Global Remicade (Infliximab) and Biosimilar Market, Segmentation by Application

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn's Disease

Other

Companies Profiled:

J & J

Pfizer

Organon

Amgen

Key Questions Answered

1. How big is the global Remicade (Infliximab) and Biosimilar market?
2. What is the demand of the global Remicade (Infliximab) and Biosimilar market?
3. What is the year over year growth of the global Remicade (Infliximab) and Biosimilar market?
4. What is the production and production value of the global Remicade (Infliximab) and Biosimilar market?
5. Who are the key producers in the global Remicade (Infliximab) and Biosimilar market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Remicade (Infliximab) and Biosimilar Introduction
- 1.2 World Remicade (Infliximab) and Biosimilar Supply & Forecast
 - 1.2.1 World Remicade (Infliximab) and Biosimilar Production Value (2018 & 2022 & 2029)
 - 1.2.2 World Remicade (Infliximab) and Biosimilar Production (2018-2029)
 - 1.2.3 World Remicade (Infliximab) and Biosimilar Pricing Trends (2018-2029)
- 1.3 World Remicade (Infliximab) and Biosimilar Production by Region (Based on Production Site)
 - 1.3.1 World Remicade (Infliximab) and Biosimilar Production Value by Region (2018-2029)
 - 1.3.2 World Remicade (Infliximab) and Biosimilar Production by Region (2018-2029)
 - 1.3.3 World Remicade (Infliximab) and Biosimilar Average Price by Region (2018-2029)
 - 1.3.4 North America Remicade (Infliximab) and Biosimilar Production (2018-2029)
 - 1.3.5 Europe Remicade (Infliximab) and Biosimilar Production (2018-2029)
 - 1.3.6 China Remicade (Infliximab) and Biosimilar Production (2018-2029)
 - 1.3.7 Japan Remicade (Infliximab) and Biosimilar Production (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Remicade (Infliximab) and Biosimilar Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Remicade (Infliximab) and Biosimilar Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

- 2.1 World Remicade (Infliximab) and Biosimilar Demand (2018-2029)
- 2.2 World Remicade (Infliximab) and Biosimilar Consumption by Region
 - 2.2.1 World Remicade (Infliximab) and Biosimilar Consumption by Region (2018-2023)
 - 2.2.2 World Remicade (Infliximab) and Biosimilar Consumption Forecast by Region (2024-2029)
- 2.3 United States Remicade (Infliximab) and Biosimilar Consumption (2018-2029)
- 2.4 China Remicade (Infliximab) and Biosimilar Consumption (2018-2029)
- 2.5 Europe Remicade (Infliximab) and Biosimilar Consumption (2018-2029)

- 2.6 Japan Remicade (Infliximab) and Biosimilar Consumption (2018-2029)
- 2.7 South Korea Remicade (Infliximab) and Biosimilar Consumption (2018-2029)
- 2.8 ASEAN Remicade (Infliximab) and Biosimilar Consumption (2018-2029)
- 2.9 India Remicade (Infliximab) and Biosimilar Consumption (2018-2029)

3 WORLD REMICADE (INFLIXIMAB) AND BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS

- 3.1 World Remicade (Infliximab) and Biosimilar Production Value by Manufacturer (2018-2023)
- 3.2 World Remicade (Infliximab) and Biosimilar Production by Manufacturer (2018-2023)
- 3.3 World Remicade (Infliximab) and Biosimilar Average Price by Manufacturer (2018-2023)
- 3.4 Remicade (Infliximab) and Biosimilar Company Evaluation Quadrant
- 3.5 Industry Rank and Concentration Rate (CR)
 - 3.5.1 Global Remicade (Infliximab) and Biosimilar Industry Rank of Major Manufacturers
 - 3.5.2 Global Concentration Ratios (CR4) for Remicade (Infliximab) and Biosimilar in 2022
 - 3.5.3 Global Concentration Ratios (CR8) for Remicade (Infliximab) and Biosimilar in 2022
- 3.6 Remicade (Infliximab) and Biosimilar Market: Overall Company Footprint Analysis
 - 3.6.1 Remicade (Infliximab) and Biosimilar Market: Region Footprint
 - 3.6.2 Remicade (Infliximab) and Biosimilar Market: Company Product Type Footprint
 - 3.6.3 Remicade (Infliximab) and Biosimilar Market: Company Product Application Footprint
- 3.7 Competitive Environment
 - 3.7.1 Historical Structure of the Industry
 - 3.7.2 Barriers of Market Entry
 - 3.7.3 Factors of Competition
- 3.8 New Entrant and Capacity Expansion Plans
- 3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

- 4.1 United States VS China: Remicade (Infliximab) and Biosimilar Production Value Comparison
 - 4.1.1 United States VS China: Remicade (Infliximab) and Biosimilar Production Value

Comparison (2018 & 2022 & 2029)

4.1.2 United States VS China: Remicade (Infliximab) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)

4.2 United States VS China: Remicade (Infliximab) and Biosimilar Production Comparison

4.2.1 United States VS China: Remicade (Infliximab) and Biosimilar Production Comparison (2018 & 2022 & 2029)

4.2.2 United States VS China: Remicade (Infliximab) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)

4.3 United States VS China: Remicade (Infliximab) and Biosimilar Consumption Comparison

4.3.1 United States VS China: Remicade (Infliximab) and Biosimilar Consumption Comparison (2018 & 2022 & 2029)

4.3.2 United States VS China: Remicade (Infliximab) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)

4.4 United States Based Remicade (Infliximab) and Biosimilar Manufacturers and Market Share, 2018-2023

4.4.1 United States Based Remicade (Infliximab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)

4.4.2 United States Based Manufacturers Remicade (Infliximab) and Biosimilar Production Value (2018-2023)

4.4.3 United States Based Manufacturers Remicade (Infliximab) and Biosimilar Production (2018-2023)

4.5 China Based Remicade (Infliximab) and Biosimilar Manufacturers and Market Share

4.5.1 China Based Remicade (Infliximab) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)

4.5.2 China Based Manufacturers Remicade (Infliximab) and Biosimilar Production Value (2018-2023)

4.5.3 China Based Manufacturers Remicade (Infliximab) and Biosimilar Production (2018-2023)

4.6 Rest of World Based Remicade (Infliximab) and Biosimilar Manufacturers and Market Share, 2018-2023

4.6.1 Rest of World Based Remicade (Infliximab) and Biosimilar Manufacturers, Headquarters and Production Site (State, Country)

4.6.2 Rest of World Based Manufacturers Remicade (Infliximab) and Biosimilar Production Value (2018-2023)

4.6.3 Rest of World Based Manufacturers Remicade (Infliximab) and Biosimilar Production (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Remicade (Infliximab) and Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Brand

5.2.2 Biosimilar

5.3 Market Segment by Type

5.3.1 World Remicade (Infliximab) and Biosimilar Production by Type (2018-2029)

5.3.2 World Remicade (Infliximab) and Biosimilar Production Value by Type (2018-2029)

5.3.3 World Remicade (Infliximab) and Biosimilar Average Price by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Remicade (Infliximab) and Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Ankylosing Spondylitis

6.2.2 Rheumatoid Arthritis

6.2.3 Crohn's Disease

6.2.4 Other

6.3 Market Segment by Application

6.3.1 World Remicade (Infliximab) and Biosimilar Production by Application (2018-2029)

6.3.2 World Remicade (Infliximab) and Biosimilar Production Value by Application (2018-2029)

6.3.3 World Remicade (Infliximab) and Biosimilar Average Price by Application (2018-2029)

7 COMPANY PROFILES

7.1 J & J

7.1.1 J & J Details

7.1.2 J & J Major Business

7.1.3 J & J Remicade (Infliximab) and Biosimilar Product and Services

7.1.4 J & J Remicade (Infliximab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)

7.1.5 J & J Recent Developments/Updates

- 7.1.6 J & J Competitive Strengths & Weaknesses
- 7.2 Pfizer
 - 7.2.1 Pfizer Details
 - 7.2.2 Pfizer Major Business
 - 7.2.3 Pfizer Remicade (Infliximab) and Biosimilar Product and Services
 - 7.2.4 Pfizer Remicade (Infliximab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
 - 7.2.5 Pfizer Recent Developments/Updates
 - 7.2.6 Pfizer Competitive Strengths & Weaknesses
- 7.3 Organon
 - 7.3.1 Organon Details
 - 7.3.2 Organon Major Business
 - 7.3.3 Organon Remicade (Infliximab) and Biosimilar Product and Services
 - 7.3.4 Organon Remicade (Infliximab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
 - 7.3.5 Organon Recent Developments/Updates
 - 7.3.6 Organon Competitive Strengths & Weaknesses
- 7.4 Amgen
 - 7.4.1 Amgen Details
 - 7.4.2 Amgen Major Business
 - 7.4.3 Amgen Remicade (Infliximab) and Biosimilar Product and Services
 - 7.4.4 Amgen Remicade (Infliximab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
 - 7.4.5 Amgen Recent Developments/Updates
 - 7.4.6 Amgen Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Remicade (Infliximab) and Biosimilar Industry Chain
- 8.2 Remicade (Infliximab) and Biosimilar Upstream Analysis
 - 8.2.1 Remicade (Infliximab) and Biosimilar Core Raw Materials
 - 8.2.2 Main Manufacturers of Remicade (Infliximab) and Biosimilar Core Raw Materials
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis
- 8.5 Remicade (Infliximab) and Biosimilar Production Mode
- 8.6 Remicade (Infliximab) and Biosimilar Procurement Model
- 8.7 Remicade (Infliximab) and Biosimilar Industry Sales Model and Sales Channels
 - 8.7.1 Remicade (Infliximab) and Biosimilar Sales Model
 - 8.7.2 Remicade (Infliximab) and Biosimilar Typical Customers

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Remicade (Infliximab) and Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)

Table 2. World Remicade (Infliximab) and Biosimilar Production Value by Region (2018-2023) & (USD Million)

Table 3. World Remicade (Infliximab) and Biosimilar Production Value by Region (2024-2029) & (USD Million)

Table 4. World Remicade (Infliximab) and Biosimilar Production Value Market Share by Region (2018-2023)

Table 5. World Remicade (Infliximab) and Biosimilar Production Value Market Share by Region (2024-2029)

Table 6. World Remicade (Infliximab) and Biosimilar Production by Region (2018-2023) & (K Units)

Table 7. World Remicade (Infliximab) and Biosimilar Production by Region (2024-2029) & (K Units)

Table 8. World Remicade (Infliximab) and Biosimilar Production Market Share by Region (2018-2023)

Table 9. World Remicade (Infliximab) and Biosimilar Production Market Share by Region (2024-2029)

Table 10. World Remicade (Infliximab) and Biosimilar Average Price by Region (2018-2023) & (US\$/Unit)

Table 11. World Remicade (Infliximab) and Biosimilar Average Price by Region (2024-2029) & (US\$/Unit)

Table 12. Remicade (Infliximab) and Biosimilar Major Market Trends

Table 13. World Remicade (Infliximab) and Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)

Table 14. World Remicade (Infliximab) and Biosimilar Consumption by Region (2018-2023) & (K Units)

Table 15. World Remicade (Infliximab) and Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)

Table 16. World Remicade (Infliximab) and Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)

Table 17. Production Value Market Share of Key Remicade (Infliximab) and Biosimilar Producers in 2022

Table 18. World Remicade (Infliximab) and Biosimilar Production by Manufacturer (2018-2023) & (K Units)

Table 19. Production Market Share of Key Remicade (Infliximab) and Biosimilar Producers in 2022

Table 20. World Remicade (Infliximab) and Biosimilar Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 21. Global Remicade (Infliximab) and Biosimilar Company Evaluation Quadrant

Table 22. World Remicade (Infliximab) and Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022

Table 23. Head Office and Remicade (Infliximab) and Biosimilar Production Site of Key Manufacturer

Table 24. Remicade (Infliximab) and Biosimilar Market: Company Product Type Footprint

Table 25. Remicade (Infliximab) and Biosimilar Market: Company Product Application Footprint

Table 26. Remicade (Infliximab) and Biosimilar Competitive Factors

Table 27. Remicade (Infliximab) and Biosimilar New Entrant and Capacity Expansion Plans

Table 28. Remicade (Infliximab) and Biosimilar Mergers & Acquisitions Activity

Table 29. United States VS China Remicade (Infliximab) and Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 30. United States VS China Remicade (Infliximab) and Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)

Table 31. United States VS China Remicade (Infliximab) and Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)

Table 32. United States Based Remicade (Infliximab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)

Table 33. United States Based Manufacturers Remicade (Infliximab) and Biosimilar Production Value, (2018-2023) & (USD Million)

Table 34. United States Based Manufacturers Remicade (Infliximab) and Biosimilar Production Value Market Share (2018-2023)

Table 35. United States Based Manufacturers Remicade (Infliximab) and Biosimilar Production (2018-2023) & (K Units)

Table 36. United States Based Manufacturers Remicade (Infliximab) and Biosimilar Production Market Share (2018-2023)

Table 37. China Based Remicade (Infliximab) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)

Table 38. China Based Manufacturers Remicade (Infliximab) and Biosimilar Production Value, (2018-2023) & (USD Million)

Table 39. China Based Manufacturers Remicade (Infliximab) and Biosimilar Production Value Market Share (2018-2023)

Table 40. China Based Manufacturers Remicade (Infliximab) and Biosimilar Production (2018-2023) & (K Units)

Table 41. China Based Manufacturers Remicade (Infliximab) and Biosimilar Production Market Share (2018-2023)

Table 42. Rest of World Based Remicade (Infliximab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)

Table 43. Rest of World Based Manufacturers Remicade (Infliximab) and Biosimilar Production Value, (2018-2023) & (USD Million)

Table 44. Rest of World Based Manufacturers Remicade (Infliximab) and Biosimilar Production Value Market Share (2018-2023)

Table 45. Rest of World Based Manufacturers Remicade (Infliximab) and Biosimilar Production (2018-2023) & (K Units)

Table 46. Rest of World Based Manufacturers Remicade (Infliximab) and Biosimilar Production Market Share (2018-2023)

Table 47. World Remicade (Infliximab) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029

Table 48. World Remicade (Infliximab) and Biosimilar Production by Type (2018-2023) & (K Units)

Table 49. World Remicade (Infliximab) and Biosimilar Production by Type (2024-2029) & (K Units)

Table 50. World Remicade (Infliximab) and Biosimilar Production Value by Type (2018-2023) & (USD Million)

Table 51. World Remicade (Infliximab) and Biosimilar Production Value by Type (2024-2029) & (USD Million)

Table 52. World Remicade (Infliximab) and Biosimilar Average Price by Type (2018-2023) & (US\$/Unit)

Table 53. World Remicade (Infliximab) and Biosimilar Average Price by Type (2024-2029) & (US\$/Unit)

Table 54. World Remicade (Infliximab) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029

Table 55. World Remicade (Infliximab) and Biosimilar Production by Application (2018-2023) & (K Units)

Table 56. World Remicade (Infliximab) and Biosimilar Production by Application (2024-2029) & (K Units)

Table 57. World Remicade (Infliximab) and Biosimilar Production Value by Application (2018-2023) & (USD Million)

Table 58. World Remicade (Infliximab) and Biosimilar Production Value by Application (2024-2029) & (USD Million)

Table 59. World Remicade (Infliximab) and Biosimilar Average Price by Application

(2018-2023) & (US\$/Unit)

Table 60. World Remicade (Infliximab) and Biosimilar Average Price by Application (2024-2029) & (US\$/Unit)

Table 61. J & J Basic Information, Manufacturing Base and Competitors

Table 62. J & J Major Business

Table 63. J & J Remicade (Infliximab) and Biosimilar Product and Services

Table 64. J & J Remicade (Infliximab) and Biosimilar Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 65. J & J Recent Developments/Updates

Table 66. J & J Competitive Strengths & Weaknesses

Table 67. Pfizer Basic Information, Manufacturing Base and Competitors

Table 68. Pfizer Major Business

Table 69. Pfizer Remicade (Infliximab) and Biosimilar Product and Services

Table 70. Pfizer Remicade (Infliximab) and Biosimilar Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 71. Pfizer Recent Developments/Updates

Table 72. Pfizer Competitive Strengths & Weaknesses

Table 73. Organon Basic Information, Manufacturing Base and Competitors

Table 74. Organon Major Business

Table 75. Organon Remicade (Infliximab) and Biosimilar Product and Services

Table 76. Organon Remicade (Infliximab) and Biosimilar Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 77. Organon Recent Developments/Updates

Table 78. Amgen Basic Information, Manufacturing Base and Competitors

Table 79. Amgen Major Business

Table 80. Amgen Remicade (Infliximab) and Biosimilar Product and Services

Table 81. Amgen Remicade (Infliximab) and Biosimilar Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)

Table 82. Global Key Players of Remicade (Infliximab) and Biosimilar Upstream (Raw Materials)

Table 83. Remicade (Infliximab) and Biosimilar Typical Customers

Table 84. Remicade (Infliximab) and Biosimilar Typical Distributors

List Of Figures

LIST OF FIGURES

- Figure 1. Remicade (Infliximab) and Biosimilar Picture
- Figure 2. World Remicade (Infliximab) and Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
- Figure 3. World Remicade (Infliximab) and Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
- Figure 4. World Remicade (Infliximab) and Biosimilar Production (2018-2029) & (K Units)
- Figure 5. World Remicade (Infliximab) and Biosimilar Average Price (2018-2029) & (US\$/Unit)
- Figure 6. World Remicade (Infliximab) and Biosimilar Production Value Market Share by Region (2018-2029)
- Figure 7. World Remicade (Infliximab) and Biosimilar Production Market Share by Region (2018-2029)
- Figure 8. North America Remicade (Infliximab) and Biosimilar Production (2018-2029) & (K Units)
- Figure 9. Europe Remicade (Infliximab) and Biosimilar Production (2018-2029) & (K Units)
- Figure 10. China Remicade (Infliximab) and Biosimilar Production (2018-2029) & (K Units)
- Figure 11. Japan Remicade (Infliximab) and Biosimilar Production (2018-2029) & (K Units)
- Figure 12. Remicade (Infliximab) and Biosimilar Market Drivers
- Figure 13. Factors Affecting Demand
- Figure 14. World Remicade (Infliximab) and Biosimilar Consumption (2018-2029) & (K Units)
- Figure 15. World Remicade (Infliximab) and Biosimilar Consumption Market Share by Region (2018-2029)
- Figure 16. United States Remicade (Infliximab) and Biosimilar Consumption (2018-2029) & (K Units)
- Figure 17. China Remicade (Infliximab) and Biosimilar Consumption (2018-2029) & (K Units)
- Figure 18. Europe Remicade (Infliximab) and Biosimilar Consumption (2018-2029) & (K Units)
- Figure 19. Japan Remicade (Infliximab) and Biosimilar Consumption (2018-2029) & (K Units)

Figure 20. South Korea Remicade (Infliximab) and Biosimilar Consumption (2018-2029) & (K Units)

Figure 21. ASEAN Remicade (Infliximab) and Biosimilar Consumption (2018-2029) & (K Units)

Figure 22. India Remicade (Infliximab) and Biosimilar Consumption (2018-2029) & (K Units)

Figure 23. Producer Shipments of Remicade (Infliximab) and Biosimilar by Manufacturer Revenue (\$MM) and Market Share (%): 2022

Figure 24. Global Four-firm Concentration Ratios (CR4) for Remicade (Infliximab) and Biosimilar Markets in 2022

Figure 25. Global Four-firm Concentration Ratios (CR8) for Remicade (Infliximab) and Biosimilar Markets in 2022

Figure 26. United States VS China: Remicade (Infliximab) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)

Figure 27. United States VS China: Remicade (Infliximab) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Remicade (Infliximab) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)

Figure 29. United States Based Manufacturers Remicade (Infliximab) and Biosimilar Production Market Share 2022

Figure 30. China Based Manufacturers Remicade (Infliximab) and Biosimilar Production Market Share 2022

Figure 31. Rest of World Based Manufacturers Remicade (Infliximab) and Biosimilar Production Market Share 2022

Figure 32. World Remicade (Infliximab) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 33. World Remicade (Infliximab) and Biosimilar Production Value Market Share by Type in 2022

Figure 34. Brand

Figure 35. Biosimilar

Figure 36. World Remicade (Infliximab) and Biosimilar Production Market Share by Type (2018-2029)

Figure 37. World Remicade (Infliximab) and Biosimilar Production Value Market Share by Type (2018-2029)

Figure 38. World Remicade (Infliximab) and Biosimilar Average Price by Type (2018-2029) & (US\$/Unit)

Figure 39. World Remicade (Infliximab) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029

Figure 40. World Remicade (Infliximab) and Biosimilar Production Value Market Share

by Application in 2022

Figure 41. Ankylosing Spondylitis

Figure 42. Rheumatoid Arthritis

Figure 43. Crohn's Disease

Figure 44. Other

Figure 45. World Remicade (Infliximab) and Biosimilar Production Market Share by Application (2018-2029)

Figure 46. World Remicade (Infliximab) and Biosimilar Production Value Market Share by Application (2018-2029)

Figure 47. World Remicade (Infliximab) and Biosimilar Average Price by Application (2018-2029) & (US\$/Unit)

Figure 48. Remicade (Infliximab) and Biosimilar Industry Chain

Figure 49. Remicade (Infliximab) and Biosimilar Procurement Model

Figure 50. Remicade (Infliximab) and Biosimilar Sales Model

Figure 51. Remicade (Infliximab) and Biosimilar Sales Channels, Direct Sales, and Distribution

Figure 52. Methodology

Figure 53. Research Process and Data Source

I would like to order

Product name: Global Remicade (Infliximab) and Biosimilar Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/GBDAB9787525EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBDAB9787525EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

